Varian Medical Systems, a manufacturer of integrated cancer therapy systems, will acquire Impac Medical Systems. Varian officials in Palo Alto, CA, see this acquisition as an important move for the company in the healthcare information systems
Varian Medical Systems, a manufacturer of integrated cancer therapy systems, will acquire Impac Medical Systems. Varian officials in Palo Alto, CA, see this acquisition as an important move for the company in the healthcare information systems field.
Impac is headquartered in Mountain View, CA. Its flagship product is the Multi-Access Oncology Management System. The company also supplies image management applications, including registration, scheduling, billing, and accounts receivable functions.
Impac has been growing at about 30% each year and the company is expecting sales of approximately $28 million for fiscal year 2000, which ends Sept. 29.
Impac President and CEO Joseph J. Jachinowski will continue in this role and will also become a corporate vice president of Varian Medical Systems.
In other Varian news, the company will begin marketing and distributing a new component to its existing real-time position management Respiratory Gating System. Respiratory gating is a technique for making cancer radiotherapy more accurate and effective by adjusting for tumor movements caused by breathing. The Varian system gates, or turns off, the radiation beam when a tumor in the chest or abdomen moves outside a prescribed target area.
The new component, called the CT Option, extends respiratory gating to the scanner so that movements recorded during imaging can be correlated with a system that controls Varians medical linear accelerators. The CT Option is being designed to work with several types of scanners from different manufacturers, including GE Medical Systems.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.